Short answer
Vera Therapeutics, Inc. (VERA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10M with net income of −$94M.
Q3 2026 key financials · XBRL
- Revenue
- $10M
- Net income
- −$94M
- −16.7% YoY · +14.4% QoQ
- Operating margin
- -931.2%
- EPS (diluted)
- −$1.29
- −2.4% YoY · +15.7% QoQ
Source: XBRL data from the Vera Therapeutics, Inc. (VERA) Q3 2026 10-Q on SEC EDGAR. USD.
Vera Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $10.3M, versus $0 YoY, entirely from TRUTAKNA sales
- Gross margin 68%, based on $10.3M revenue and $3.3M cost of sales
- Net loss $93.7M vs $80.3M YoY, with operating expenses $106.0M vs $83.9M
- Cash, equivalents and marketable securities $384.0M vs $714.6M at December 31, 2025
- Nine-month operating cash outflow $305.9M vs $171.1M, with $9.6M financing inflow and $75.0M debt draw in October 2026
- Near-term outlook: continued losses and rising R&D, SG&A and capital expenditures, with liquidity expected for at least 12 months
Risk Factors
- Newly heightened commercialization risk: FDA accelerated approval of TRUTAKNA on July 7, 2026 created post-approval study and commercial execution obligations
- Regulatory risk: confirmatory eGFR study failure could trigger accelerated-approval withdrawal after approval based on UPCR results
- Operational risk: limited commercialization experience and newly building sales, market-access, and distribution capabilities
- Competitive risk: Roche’s GAZYVA received FDA Priority Review in July 2026 for pMN, with a decision expected by November 2026
- Financial risk: $150.0 million outstanding under the 2025 Loan Agreement as of October 31, 2026, with covenant-related acceleration exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vera Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.